Cargando…

Zolpidem pharmacokinetics and pharmacodynamics in metabolic interactions involving CYP3A: sex as a differentiating factor

Detalles Bibliográficos
Autores principales:	Cubała, Wiesław Jerzy, Wiglusz, Mariusz, Burkiewicz, Anna, Gałuszko-Węgielnik, Maria
Formato:	Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2010
Materias:	Letter to the Editors
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2921491/ https://www.ncbi.nlm.nih.gov/pubmed/20552178 http://dx.doi.org/10.1007/s00228-010-0854-x

Ejemplares similares

Antianhedonic Effect of Repeated Ketamine Infusions in Patients With Treatment Resistant Depression
por: Wilkowska, Alina, et al.
Publicado: (2021)

Central nervous system-related safety and tolerability of add-on ketamine to standard of care treatment in treatment-resistant psychotic depression in patients with major depressive disorder and bipolar disorder
por: Gałuszko-Wȩgielnik, Maria, et al.
Publicado: (2023)

Intravenous Ketamine Infusions in Treatment-Resistant Bipolar Depression: An Open-Label Naturalistic Observational Study
por: Wilkowska, Alina, et al.
Publicado: (2021)

Effect of CYP3A4 metabolism on sex differences in the pharmacokinetics and pharmacodynamics of zolpidem
por: Yoon, Seonghae, et al.
Publicado: (2021)

Ketamine as Add-On Treatment in Psychotic Treatment-Resistant Depression
por: Gałuszko-Węgielnik, Maria, et al.
Publicado: (2023)

Magnesium in Ketamine Administration in Treatment-Resistant Depression
por: Górska, Natalia, et al.
Publicado: (2021)

Metabolic Risk Factors and Cardiovascular Safety in Ketamine Use for Treatment Resistant Depression
por: Szarmach, Joanna, et al.
Publicado: (2020)

Somatic Comorbidities and Cardiovascular Safety in Ketamine Use for Treatment-Resistant Depression
por: Szarmach, Joanna, et al.
Publicado: (2021)

Affective Switch Associated With Oral, Low Dose Ketamine Treatment in a Patient With Treatment Resistant Bipolar I Depression. Case Report and Literature Review
por: Wilkowska, Alina, et al.
Publicado: (2020)

Copper Concentrations in Ketamine Therapy for Treatment-Resistant Depression
por: Słupski, Jakub, et al.
Publicado: (2020)

Central nervous system-related safety and tolerability of add-on ketamine to antidepressant medication in treatment-resistant depression: focus on the unique safety profile of bipolar depression
por: Włodarczyk, Adam, et al.
Publicado: (2021)

Dissociative symptoms with intravenous ketamine in treatment-resistant depression exploratory observational study
por: Włodarczyk, Adam, et al.
Publicado: (2021)

Case Report: Repeated Series of Ketamine Infusions in Patients With Treatment-Resistant Depression: Presentation of Five Cases
por: Gałuszko-Wȩgielnik, Maria, et al.
Publicado: (2021)

Severe skin complications in patients treated with antidepressants: a literature review
por: Herstowska, Marta, et al.
Publicado: (2014)

Comment on ‘The overlapping relationship among depression, anxiety, and somatic symptom disorder and its impact on the quality of life of people with epilepsy’
por: Grzegorzewska, Agata M., et al.
Publicado: (2023)

Cortisol awakening response in drug-naïve panic disorder
por: Jakuszkowiak-Wojten, Katarzyna, et al.
Publicado: (2016)

Daytime pharmacodynamic and pharmacokinetic evaluation of low-dose sublingual transmucosal zolpidem hemitartrate
por: Roth, Thomas, et al.
Publicado: (2008)

Clozapine in Treatment-Resistant Bipolar Disorder With Suicidality. Three Case Reports
por: Wilkowska, Alina, et al.
Publicado: (2019)

ZOLPIDEM INDUCED DELIRIUM
por: Sidana, Ajeet, et al.
Publicado: (2002)

Ketamine and Lamotrigine Combination in Psychopharmacology: Systematic Review
por: Wilkowska, Alina, et al.
Publicado: (2022)

A case of suicide attempt with Zolpidem - will Zolpidem show up on standard urine toxicology screening?
por: Willner, Nadav, et al.
Publicado: (2014)

Exploring the Relationship between Mood Disorders and Coexisting Health Conditions: The Focus on Nutraceuticals
por: Mechlińska, Agnieszka, et al.
Publicado: (2023)

Multiple Comorbidity Profile of Psychiatric Disorders in Epilepsy
por: Grzegorzewska, Agata M., et al.
Publicado: (2021)

Comparative pharmacokinetics of zolpidem tartrate in five ethnic populations of China
por: Guo, Tao, et al.
Publicado: (2014)

Sleep-Walking with Zolpidem: Need for Continued Postmarketing Surveillance
por: Sharma, Ajitha, et al.
Publicado: (2015)

Zolpidem dependence for self-medication in the management of tardive dyskinesia
por: Fan, Chiung-Yueh, et al.
Publicado: (2023)

Dysphoria and Irritability—Diagnostic Pitfalls in the Assessment of Interictal Dysphoric Disorder in Epilepsy
por: Grzegorzewska, Agata M., et al.
Publicado: (2021)

Proteasome Inhibitors and Their Pharmacokinetics, Pharmacodynamics, and Metabolism
por: Wang, Jinhai, et al.
Publicado: (2021)

Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Predict the Impact of CYP2C9 Genetic Polymorphisms, Co-Medication and Formulation on the Pharmacokinetics and Pharmacodynamics of Flurbiprofen
por: Loisios-Konstantinidis, Ioannis, et al.
Publicado: (2020)

Zolpidem: A masked hero. A reply to ZORRO study
por: Lugoboni, Fabio, et al.
Publicado: (2021)

Why zolpidem increases the risk of falls and fractures in patients with cirrhosis
por: Weersink, Rianne Antoinet, et al.
Publicado: (2022)

Melatonin as a Potential Adjuvant Treatment for COVID-19 beyond Sleep Disorders
por: Wichniak, Adam, et al.
Publicado: (2021)

Delayed-Onset Hepatic Encephalopathy Induced by Zolpidem: A Case Report
por: da Silva, Vitor Carlos Santos, et al.
Publicado: (2008)

Influence of CYP2D6 and CYP3A5 Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Bisoprolol in Hypertensive Chinese Patients
por: Chan, Sze Wa, et al.
Publicado: (2021)

Effects of Age and Sex on the Single-Dose Pharmacokinetics and Pharmacodynamics of Apixaban
por: Frost, Charles E., et al.
Publicado: (2015)

Impact of CYP3A4*1G Allele on Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel
por: Danielak, Dorota, et al.
Publicado: (2016)

Phase I Studies of Acebilustat: Pharmacokinetics, Pharmacodynamics, Food Effect, and CYP3A Induction
por: Elborn, JS, et al.
Publicado: (2016)

Zolpidem withdrawal delirium
por: Mattoo, Surendra K., et al.
Publicado: (2011)

Zolpidem for the Treatment of Dystonia
por: Badillo, Stephanie Patricia J., et al.
Publicado: (2019)

A Study on CYP2C19 and CYP2D6 Polymorphic Effects on Pharmacokinetics and Pharmacodynamics of Amitriptyline in Healthy Koreans
por: Ryu, S, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7kl0nsbb4o89vs5d6d3ar33koq